SIM
NVO

Sentry Investment Management’s Novo Nordisk NVO Stock Holding History

Sentry Investment Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-49,000
Closed -$829K – 533
2013
Q3 		$829K Hold
49,000
– – 0.05% 281
2013
Q2 		$759K Buy
+49,000
New +$816K 0.04% 204

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
TIM
Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
MAA
Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Sentry Investment Management's NVO Position: Q4 2013 in Review

Sentry Investment Management sold out of Novo Nordisk (NVO) in Q4 2013, closing a stake of 49,000 shares — an estimated $829K sold.

Sentry Investment Management first reported a position in NVO in Q2 2013 and held it in 2 quarters. The position peaked at $829K in Q3 2013. 431 funds tracked by Wall St. Rank hold NVO as of Q4 2013.

  • Sentry Investment Management reported no remaining Novo Nordisk position as of Q4 2013 after selling out during the quarter.
  • Sentry Investment Management sold 49,000 Novo Nordisk shares in Q4 2013, an estimated $829K.
  • Sentry Investment Management first reported a position in Novo Nordisk in Q2 2013 and held it in 2 quarters.
  • Sentry Investment Management's Novo Nordisk position peaked at $829K in Q3 2013.
  • 431 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2013.

Based on Sentry Investment Management's 13F filing for Q4 2013, filed 10 Feb 2014.